Gosset Ownership
Private
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Livionex General Information
Livionex has reported positive end-of-phase 2 results with its C-KAD eye drop for early-to-moderate cataracts and is preparing to advance to Phase 3 trials. Its LIVFRESH toothpaste is approved in Europe and commercially available. The company’s technology platform targets metal ions implicated in disease pathways such as oxidative stress and inflammation. Other programs are at preclinical or early clinical stages.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Los Gatos, California
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Collaborations with major US universities; specific partners not named publicly, No major pharma partnerships disclosed.
Livionex Funding
No funding data available
To view Livionex's complete valuation and funding history, request access »